Tokyo Tape
Sign in
← Qol Holdings

Half-year report · Q2

3034.TEDINET S100URNY
Period2024-04-01 → 2024-09-30
Filed2024-11-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
MetricValuePeriodScopeSource row
Revenue¥124.8bn2024-04-01 → 2024-09-30Cons.Net sales
Revenue¥180.1bn2023-04-01 → 2024-03-31Cons.Net sales (5-year summary)
Revenue¥88.5bn2023-04-01 → 2023-09-30Cons.Net sales
Operating income¥6.1bn2024-04-01 → 2024-09-30Cons.Operating income
Operating income¥3.6bn2023-04-01 → 2023-09-30Cons.Operating income
Ordinary income¥6.2bn2024-04-01 → 2024-09-30Cons.Ordinary income
Ordinary income¥9.3bn2023-04-01 → 2024-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥3.7bn2023-04-01 → 2023-09-30Cons.Ordinary income
Profit before tax¥5.0bn2024-04-01 → 2024-09-30Cons.Income before income taxes
Profit before tax¥3.6bn2023-04-01 → 2023-09-30Cons.Income before income taxes
Net income (owners)¥1.2bn2024-04-01 → 2024-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥4.9bn2023-04-01 → 2024-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥1.9bn2023-04-01 → 2023-09-30Cons.Profit loss attributable to owners of parent
Net income¥2.3bn2024-04-01 → 2024-09-30Cons.Profit loss
Net income¥1.9bn2023-04-01 → 2023-09-30Cons.Profit loss
Total assets¥137.3bnat 2024-09-30Cons.Assets
Total assets¥117.8bnat 2024-03-31Cons.Assets
Total assets¥107.4bnat 2023-09-30Cons.Total assets (5-year summary)
Total liabilities¥79.3bnat 2024-09-30Cons.Liabilities
Total liabilities¥64.9bnat 2024-03-31Cons.Liabilities
Net assets / equity¥58.0bnat 2024-09-30Cons.Net assets
Net assets / equity¥52.8bnat 2024-03-31Cons.Net assets
Net assets / equity¥50.3bnat 2023-09-30Cons.Net assets (5-year summary)
Cash and deposits¥21.8bnat 2024-09-30Cons.Cash and deposits
Cash and deposits¥27.3bnat 2024-03-31Cons.Cash and deposits
Cash & equivalents¥21.5bnat 2024-09-30Cons.Cash and cash equivalents
Cash & equivalents¥26.9bnat 2024-03-31Cons.Cash and cash equivalents
Cash & equivalents¥17.3bnat 2023-09-30Cons.Cash and cash equivalents
Cash & equivalents¥18.6bnat 2023-03-31dCons.Cash and cash equivalents
Operating cash flow¥477m2024-04-01 → 2024-09-30Cons.Net cash provided by used in operating activities
Operating cash flow¥13.5bn2023-04-01 → 2024-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥6.4bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in operating activities
Investing cash flow¥265m2024-04-01 → 2024-09-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥13.2bn2023-04-01 → 2024-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥9.9bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in investment activities
Financing cash flow−¥6.2bn2024-04-01 → 2024-09-30Cons.Net cash provided by used in financing activities
Financing cash flow¥8.0bn2023-04-01 → 2024-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow¥2.2bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in financing activities
EPS (basic)¥32.432024-04-01 → 2024-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥131.112023-04-01 → 2024-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥50.82023-04-01 → 2023-09-30Cons.Basic earnings loss per share (5-year summary)
Equity ratio39.3%at 2024-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio44.8%at 2024-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio46.8%at 2023-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 36
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2024-04-01 → 2024-09-30−¥686m
Reconciling Itemsreconcilingrevenue intersegment2024-04-01 → 2024-09-30−¥686m
Reconciling Itemsreconcilingsegment profit2024-04-01 → 2024-09-30−¥1.8bn
jpcrp040300-q2r_E03476-000Health Insurance Pharmacyreportable segmentrevenue2024-04-01 → 2024-09-30¥84.1bn
jpcrp040300-q2r_E03476-000Health Insurance Pharmacyreportable segmentrevenue external2024-04-01 → 2024-09-30¥84.1bn
jpcrp040300-q2r_E03476-000Health Insurance Pharmacyreportable segmentrevenue intersegment2024-04-01 → 2024-09-30¥64m
jpcrp040300-q2r_E03476-000Health Insurance Pharmacyreportable segmentsegment profit2024-04-01 → 2024-09-30¥4.2bn
jpcrp040300-q2r_E03476-000Medical Relatedreportable segmentrevenue2024-04-01 → 2024-09-30¥7.4bn
jpcrp040300-q2r_E03476-000Medical Relatedreportable segmentrevenue external2024-04-01 → 2024-09-30¥6.8bn
jpcrp040300-q2r_E03476-000Medical Relatedreportable segmentrevenue intersegment2024-04-01 → 2024-09-30¥622m
jpcrp040300-q2r_E03476-000Medical Relatedreportable segmentsegment profit2024-04-01 → 2024-09-30¥928m
jpcrp040300-q2r_E03476-000Pharmaceutical Businessreportable segmentrevenue2024-04-01 → 2024-09-30¥33.9bn
jpcrp040300-q2r_E03476-000Pharmaceutical Businessreportable segmentrevenue external2024-04-01 → 2024-09-30¥33.9bn
jpcrp040300-q2r_E03476-000Pharmaceutical Businessreportable segmentsegment profit2024-04-01 → 2024-09-30¥2.7bn
—segment totalrevenue2024-04-01 → 2024-09-30¥125.5bn
—segment totalrevenue external2024-04-01 → 2024-09-30¥124.8bn
—segment totalrevenue intersegment2024-04-01 → 2024-09-30¥686m
—segment totalsegment profit2024-04-01 → 2024-09-30¥7.9bn
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-09-30−¥237m
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-09-30−¥237m
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-09-30−¥1.8bn
jpcrp040300-q2r_E03476-000Health Insurance Pharmacyreportable segmentrevenue2023-04-01 → 2023-09-30¥81.0bn
jpcrp040300-q2r_E03476-000Health Insurance Pharmacyreportable segmentrevenue external2023-04-01 → 2023-09-30¥81.0bn
jpcrp040300-q2r_E03476-000Health Insurance Pharmacyreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥63m
jpcrp040300-q2r_E03476-000Health Insurance Pharmacyreportable segmentsegment profit2023-04-01 → 2023-09-30¥4.7bn
jpcrp040300-q2r_E03476-000Medical Relatedreportable segmentrevenue2023-04-01 → 2023-09-30¥6.8bn
jpcrp040300-q2r_E03476-000Medical Relatedreportable segmentrevenue external2023-04-01 → 2023-09-30¥6.7bn
jpcrp040300-q2r_E03476-000Medical Relatedreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥173m
jpcrp040300-q2r_E03476-000Medical Relatedreportable segmentsegment profit2023-04-01 → 2023-09-30¥801m
jpcrp040300-q2r_E03476-000Pharmaceutical Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥897m
jpcrp040300-q2r_E03476-000Pharmaceutical Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥897m
jpcrp040300-q2r_E03476-000Pharmaceutical Businessreportable segmentsegment profit2023-04-01 → 2023-09-30−¥142m
—segment totalrevenue2023-04-01 → 2023-09-30¥88.8bn
—segment totalrevenue external2023-04-01 → 2023-09-30¥88.5bn
—segment totalrevenue intersegment2023-04-01 → 2023-09-30¥237m
—segment totalsegment profit2023-04-01 → 2023-09-30¥5.4bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 543
ItemContextValueUnit
Gross profitPrior1YTDDuration11031000000JPY
Gross profitCurrentYTDDuration19049000000JPY
Selling general and administrative expensesPrior1YTDDuration7472000000JPY
Selling general and administrative expensesCurrentYTDDuration12953000000JPY
Operating incomePrior1YTDDuration3559000000JPY
Operating incomeCurrentYTDDuration6096000000JPY
House rent income noiPrior1YTDDuration62000000JPY
House rent income noiCurrentYTDDuration72000000JPY
Commission fee noiPrior1YTDDuration73000000JPY
Commission fee noiCurrentYTDDuration30000000JPY
Insurance premiums refunded cancellation noiPrior1YTDDuration1000000JPY
Insurance premiums refunded cancellation noiCurrentYTDDuration25000000JPY
Subsidy income noiPrior1YTDDuration4000000JPY
Subsidy income noiCurrentYTDDuration3000000JPY
Guarantee commission received noiPrior1YTDDuration29000000JPY
Guarantee commission received noiCurrentYTDDuration29000000JPY
Subsidy income noi bountyPrior1YTDDuration21000000JPY
Subsidy income noi bountyCurrentYTDDuration81000000JPY
Other noiPrior1YTDDuration41000000JPY
Other noiCurrentYTDDuration57000000JPY
Non operating incomePrior1YTDDuration235000000JPY
Non operating incomeCurrentYTDDuration300000000JPY
Interest expenses noePrior1YTDDuration51000000JPY
Interest expenses noeCurrentYTDDuration97000000JPY
Rent expenses noePrior1YTDDuration34000000JPY
Rent expenses noeCurrentYTDDuration35000000JPY
Other noePrior1YTDDuration32000000JPY
Other noeCurrentYTDDuration43000000JPY
Non operating expensesPrior1YTDDuration118000000JPY
Non operating expensesCurrentYTDDuration176000000JPY
Ordinary incomePrior1YTDDuration3675000000JPY
Ordinary incomeCurrentYTDDuration6220000000JPY
Gain on sales of noncurrent assets eiPrior1YTDDuration1000000JPY
Gain on sales of noncurrent assets eiCurrentYTDDuration6000000JPY
Extraordinary incomePrior1YTDDuration1000000JPY
Extraordinary incomeCurrentYTDDuration6000000JPY
Loss on retirement of noncurrent assets elPrior1YTDDuration14000000JPY
Loss on retirement of noncurrent assets elCurrentYTDDuration42000000JPY
Loss on sales of noncurrent assets elPrior1YTDDuration10000000JPY
Loss on sales of noncurrent assets elCurrentYTDDuration4000000JPY
Loss on withdrawal from employees pension fund elPrior1YTDDuration38000000JPY
Loss on withdrawal from employees pension fund elCurrentYTDDuration－JPY
Directors retirement benefits elPrior1YTDDuration－JPY
Directors retirement benefits elCurrentYTDDuration957000000JPY
Loss on step acquisitions elPrior1YTDDuration－JPY
Loss on step acquisitions elCurrentYTDDuration214000000JPY
Other elPrior1YTDDuration1000000JPY
Other elCurrentYTDDuration6000000JPY
Extraordinary lossPrior1YTDDuration64000000JPY
Extraordinary lossCurrentYTDDuration1225000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2024-03-31pass rounding
balance sheet identityconsolidated 2024-09-30pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2024-03-31pass
statement vs summary · net assetsconsolidated 2024-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-09-30pass
statement vs summary · net income attributable to parentconsolidated 2024-04-01/2024-09-30pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-09-30pass
statement vs summary · operating cash flowconsolidated 2024-04-01/2024-09-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-09-30pass
statement vs summary · revenueconsolidated 2024-04-01/2024-09-30pass
statement vs summary · total assetsconsolidated 2024-03-31pass
statement vs summary · total assetsconsolidated 2024-09-30pass